News

Study finds no link between thyroid function and MCI


 

Neither clinical nor subclinical hypothyroidism was associated with mild cognitive impairment in a large, population-based study.

Among almost 2,000 elderly subjects, mild cognitive impairment (MCI) was present in 16% of those with normal thyroid function, 17% of those with clinical hypothyroidism, and 18% of those with subclinical hypothyroidism, Dr. Ajay K. Parsaik and his colleagues reported in the Dec. 30 issue of JAMA Neurology (doi:10.1001/jamaneurol.2013.5402).

The findings question the usefulness of pursuing thyroid status as a possible contributor to MCI, wrote Dr. Parsaik of the department of psychiatry and behavior sciences, University of Texas Medical School, Houston, and his coauthors.

"Cognitive decline and thyroid dysfunction are common in the elderly, and a widely held view is that hypothyroidism is a reversible risk factor for cognitive impairment, even though several studies have shown no such association. Our population-based findings also argue against an association and suggest that neither clinical nor subclinical hypothyroidism is a risk factor for MCI. .... This raises questions about the need for routine testing of thyroid function as a part of the diagnostic work-up in patients with MCI."

The team examined thyroid function and cognitive status among 1,904 elderly subjects who were included in the Olmsted County (Minn.) health care records database. Most (1,588; 83%) were cognitively normal; 316 had MCI. Those with MCI were older (82 vs. 80 years), less educated (13 vs. 14 years), and more often carriers of the apolipoprotein E4 risk gene (30% vs. 22%).

Medical comorbidities, including hypertension, coronary artery disease, diabetes, stroke, and depression were significantly more common among those with MCI.

Most subjects (1,450) had normal thyroid function. Of these, 84% were cognitively normal and 16% had MCI.

Clinical hypothyroidism was present in 313; of these, 83% were cognitively normal, and 17% had MCI. All subjects were taking thyroid replacement therapy.

Subclinical hypothyroidism was present in 141; of these, 83% were cognitively normal and 18% had MCI. None of these subjects were getting thyroid replacement therapy.

In an analysis that controlled for age, education, sex, APOE E4 status, depression, and medical comorbidities, MCI was not significantly associated with either clinical or subclinical hypothyroidism. There was no significant interaction between APOE E4 status and hypothyroidism.

The authors noted that their findings should be validated in a larger, longitudinal study in a more varied population.

The study was sponsored by the National Institutes of Health. Dr. Parsaik had no financial disclosures. One of the coauthors, Dr. Bradley Boeve, reported multiple disclosures, some with pharmaceutical companies.

msullivan@frontlinemedcom.com

Recommended Reading

HT yields no cognitive harm or benefit
MDedge Endocrinology
Insulin boosted memory in patients with high-risk Alzheimer's allele
MDedge Endocrinology
Slight cognition benefit found for testosterone gel after menopause
MDedge Endocrinology
Glucose, insulin measures unrelated to AD pathology
MDedge Endocrinology
Metformin bests other antidiabetics in protection from dementia
MDedge Endocrinology
Brain volume loss may be greater in type 1 diabetics with microangiopathy
MDedge Endocrinology
Higher glucose linked to increased dementia risk
MDedge Endocrinology
High-dose, high-potency statins reduced dementia risk
MDedge Endocrinology
Breast cancer hormone therapy may affect cognitive function
MDedge Endocrinology
Daily multivitamin didn’t preserve cognitive function in men
MDedge Endocrinology